April 21 Quick Takes: Reify’s big round to support clinical trial diversity
Plus Terran gains rights to two late-stage candidates from Sanofi, and updates from Ampio, Nephris, Jacobus and more
Software and clinical trial infrastructure company Reify Health Inc. intends to support its new diversity and inclusion initiative with a $220 million series D round, with leaders Altimeter Capital and Coatue joining Dragoneer Investment Group and existing investors ICONIQ Growth, Adams Street, and Battery Ventures. Reify’s Bringing Representation, Inclusion, and Diversity to Global Enrollment (BRIDGE) initiative aims to identify barriers to representation in trials and find ways to make them more inclusive. FDA’s recent draft guidance calls for sponsors to create diversity plans before starting trials.
A deal with Sanofi (Euronext:SAN; NASDAQ:SNY) has given Terran Biosciences Inc. rights to two assets it describes as late-stage candidates for neurological and psychiatric indications. The private biotech isn’t naming the assets and hasn’t disclosed terms of the deal, although it said the products have been tested in 104 clinical trials and have generated four INDs. Terran said its portfolio includes psychedelic-based therapeutics...